Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heparin gel for hand-foot syndrome in capecitabine-treated cancer patients
IRCT20230215057423N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Apr 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of heparin in Erythrodysesthesia syndrome (PPE), sponsored by Shahrekord University of Medical Sciences. Started Apr 2023; status: completed.
02
Drugs
heparin
03
Conditions
Erythrodysesthesia syndrome (PPE)
Beyond the preview
Go deeper on IRCT20230215057423N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230215057423N1.